OncoSec Announces Research Collaboration with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy (IVM), TAVO-PLUS and APOLLO™ Electroporation Generator

Jun 17, 2019 8:30am EDT

OncoSec to Present Immunological Data at World Pharma Week 2019

Jun 13, 2019 8:30am EDT

OncoSec Announces Collaboration For TAVO™ In Australia With Emerge Health

May 29, 2019 8:30am EDT

OncoSec Medical Incorporated Announces Closing of $11.0 Million Public Offering and Terminates ATM and Other Financing Facility

May 28, 2019 8:30am EDT

UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec’s TAVO™, Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer

May 23, 2019 8:30am EDT

OncoSec Medical Incorporated Prices $11,000,000 Public Offering

May 22, 2019 8:45am EDT

OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer

May 22, 2019 8:30am EDT

OncoSec Medical Incorporated Announces Proposed Public Offering

May 21, 2019 4:01pm EDT

OncoSec Granted Exclusive Worldwide Rights To A Patent Portfolio For The Combination Use Of IL-12 DNA With Checkpoint Inhibitors To Treat Cancer In Several Key Countries

May 21, 2019 8:30am EDT

OncoSec Announces 1-for-10 Reverse Stock Split

May 20, 2019 12:45pm EDT